1-4 of 4
Sejal Badre
Close
Sort by
Journal Articles

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Uwe Platzbecker, MD, Argiris Symeonidis, MD PhD, Jeroen Simon Goede, Agnes Guerci-Bresler, Michel Delforge, MDPhD, Esther Natalie Oliva, MD, Jiri Mayer, Prof, MD SCs, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao
Journal: Blood
Blood (2017) 130 (Supplement 1): 4271.
https://doi.org/10.1182/blood.V130.Suppl_1.4271.4271
Published: 2017
Journal Articles

Darbepoetin Alfa for the Treatment of Anemic Patients with Myelodysplastic Syndrome: A Belgian Single-Arm, Companion Trial to the Arcade Phase 3 Study

Michel Delforge, Dominiek Mazure, Isabelle Vande Broek, Jo Caers, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao
Journal: Blood
Blood (2017) 130 (Supplement 1): 5318.
https://doi.org/10.1182/blood.V130.Suppl_1.5318.5318
Published: 2017
Journal Articles

A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)

Uwe Platzbecker, MD, Argiris Symeonidis, Esther N. Oliva, Jeroen S. Goede, Michel Delforge, Jiri Mayer, Borhane Slama, Sejal Badre, Eduard Gasal, Bhakti Mehta, Janet Franklin
Journal: Blood
Blood (2016) 128 (22): 2010.
https://doi.org/10.1182/blood.V128.22.2010.2010
Published: 2016
Journal Articles

Pegfilgrastim Use Associated with Lower Risk of Hospitalization Than Filgrastim Use: A Retrospective US Claims Analysis.

Arash Naeim, MD, Henry J Henk, PhD, Laura Becker, MS, Victoria Chia, PhD, Sejal Badre, MS, Robert G Deeter, PharmD
Journal: Blood
Blood (2010) 116 (21): 3801.
https://doi.org/10.1182/blood.V116.21.3801.3801
Published: 2010